[1] [1] KHAN I, YOUSIF A, CHENSNOKOV M, et al. A decade of cell death studies: breathing new life into necroptosis［J］. Pharmacology & Therapeutics, 2020, 11(1): 107717.

[2] [2] Chen J, Yang X, Fang X, et al. The role of ferroptosis in chronic diseases［J］. Journal of Zhejiang University (Medical Sciences), 2020, 49(1): 44-57.

[3] [3] Dolma S, Lessnick S L, Hahn W C, et al. Identification of genotype-selective antitumor agents using synthetic lethal chemical screening in engineered human tumells［J］. Cancer Cell, 2003, 285(6):?285-296.

[4] [4] YAGODA N, VON RECHENBERG M, ZAGANJOR E, et al. RAS-RAF-MEK-dependent oxidative cell death involving voltage-dependent anion channels［J］. Nature, 2007, 447(7146): 864-868.

[5] [5] CHEN X, YU C, KANG R, et al. Iron metabolism in ferroptosis［J］. Frontiers in Cell and Developmental Biology, 2020, 8: 590226.

[6] [6] DIXON S, LEMBERG K, LAMPRECHT M, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death［J］. Cell, 2012, 149(5): 1060-1072.

[7] [7] YANG W S, STOCKWELL B R. Synthetic lethal screening identifies compounds activating iron-dependent, nonapoptotic cell death in oncogenic-RAS-harboring cancer cells［J］. Chemistry & Biology, 2008, 15(3): 234-245.

[8] [8] ALVAREZ S W, SVIDERSKIY V O, TERZI E M, et al. NFS1 undergoes positive selection in lung tumours and protects cells from ferroptosis［J］. Nature, 2017, 551(7682): 639-643.

[9] [9] FANG X, WANG H, HAN D, et al. Ferroptosis as a target for protection against cardiomyopathy［J］. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116(7): 2672-2680.?

[10] [10] CHANG L C, CHIANG S K, CHEN S E, et al. Heme oxygenase-1 mediates BAY 11-7085 induced ferroptosis［J］. Cancer Letters, 2018, 416: 124-137.

[11] [11] IMAI H, MATSUOKA M, KUMAGAI T, et al. Lipid peroxidation-dependent cell death regulated by GPX4 and ferroptosis［J］. Current Topics in Microbiology and Immunology, 2017, 403: 143-170.?

[12] [12] MIOTTO G, ROSSETTO M, ROVERI A, et al. Insight into the mechanism of ferroptosis inhibition by ferrostatin-1［J］. Redox Biology, 2020, 28: 101328.

[13] [13] YANG W, SRIRAMARATNAM R, WELSCH M, et al. Regulation of ferroptotic cancer cell death by GPX4［J］. Cell, 2014, 156(1/2): 317-331.

[14] [14] GASCHLER M M, ANDIA A A, LIU H, et al. FINO2 initiates ferroptosis through GPX4 inactivation and iron oxidation［J］. Nature Chemical Biology, 2018, 14(5): 507-515.

[15] [15] TANG D, KROEMER G. Ferroptosis［J］. Current Biology, 2020, 30(21): R1292-R1297.

[16] [16] YAN B, AI Y, SUN Q, et al. Membrane damage during ferrop0tosis is caused by oxidation of phospholipids catalyzed by the oxidoreductases por and cyb5r1［J］. Molecular Cell, 2020, 81(2): 355-369.

[17] [17] DOLL S, PRONETH B, TYURINA Y Y, et al. ACSL4 dictates ferroptosis sensitivity by shaping cellular lipid composition［J］. Nature Chemical Biology, 2016, 13(1): 91-98.

[18] [18] LIU Y, TAVANA O, GU W, et al. P53 modifications: exquisite decorations of the powerful guardian［J］. Journal of Molecular Cell Biology, 2019, 11(7): 564-577.

[19] [19] WANG L, LIU Y, DU T, et al. ATF3 promotes ferroptosis by suppressing system xc-［J］. Chinese Journal of Pharmacology and Toxicology, 2020, 27(2): 662-675.?

[20] [20] KANG R, ZHU S, ZEH H J, et al. BECN1 is a new driver of ferroptosis［J］. Autophagy, 2018, 14(12): 2173-2175.

[21] [21] KON N, OU Y, WANG S J, et al. mTOR inhibition acts as an unexpected checkpoint in p53-mediated tumor suppression［J］. Genes & Development, 2021, 35(1/2): 59-64.

[22] [22] JIANG L, KON N, LI T, et al. Ferroptosis as a p53-mediated activity during tumour suppression［J］. Nature, 2015, 520(7545): 57-62.

[23] [23] CHU B, KON N, CHEN D, et al. Alox12 is required for p53-mediated tumour suppression through a distinct ferroptosis pathway［J］. Nature Cell Biology, 2019, 21(5): 579-591.

[24] [24] TARANGELO A, MAGTANONG L, BIEGING-ROLETT K T, et al. P53 suppresses metabolic stress-induced ferroptosis in cancer cells［J］. Cell Reports, 22(3): 569-575.

[25] [25] XIE Y, ZHU S, SONG X, et al. The tumor suppressor p53 limits ferroptosis by blocking DPP4 activity［J］. Cell Reports,?2017, 20(7): 1692-1704.

[26] [26] MAZURE N M. Vdac in cancer［J］. Biochimica et Biophysica Acta-Bioenergetics,?2017, 1858(8): 665-673.

[27] [27] DOLL S, FREITAS F P, SHAH R, et al. FSP1 is a glutathione-independent ferroptosis suppressor［J］. Nature, 2019, 575(7784): 693-698.

[28] [28] YI J, ZHU J, WU J, et al. Oncogenic activation of PI3K-AKT-mTOR signaling suppresses ferroptosis via SREBP-mediated lipogenesis［J］. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117(49): 31189-31197.

[29] [29] LI J, CAO F, YIN H L, et al. Ferroptosis: past, present and future［J］. Cell Death & Disease, 2020, 11(2): 88-91.

[31] [31] SIEGEL R L, MILLER K D, JEMAL A. Cancer statistics［J］. CA: A Cancer Journal for Clinicians, 2019, 69(1): 7-34.

[32] [32] ZOU Y, PALTE M J, DEIK A A, et al. A GPX4-dependent cancer cell state underlies the clear-cell morphology and confers sensitivity toferroptosis［J］. Nature Communications, 2019, 10(1): 1617.

[33] [33] MIESS H, DANKWORTH B, GOUW A M, et al. The glutathione redox system is essential to prevent ferroptosis caused by impaired lipid metabolism in clear cell renal cell carcinoma［J］. Oncogene, 2018, 37(40): 5435-5450.

[34] [34] MOU Y, WU J, ZHANG Y, et al. Low expression of ferritinophagy-related NCOA4 gene in relation to unfavorable outcome and defective immune cells infiltration in clear cell renal carcinoma［J］. BMC Cancer, 2021, 21(1): 18.

[35] [35] SLEZAKOVA S, RUDA-KUCEROVA J. Anticancer activity of artemisinin and its derivatives［J］. Anticancer Research, 2017, 37(11): 5995-6003.

[36] [36] MARKOWITSCH S D, SCHUPP P, LAUCKNER J, et al. Artesunate inhibits growth of sunitinib-resistant renal cell carcinoma cells through cell cycle arrest and induction of ferroptosis［J］. Cancers, 2020, 12(11): 3150.

[37] [37] OOI A. Advances in hereditary leiomyomatosis and renal cell carcinoma (HLRCC) research［J］. Seminars Cancer Biology, 2020, 61: 158-166.

[38] [38] MICHAEL J. Ironing out roles and regulation of NRF2 in a hereditary cancer syndrome［J］. Seminars in Cancer Biology, 2019, 109(9): 2757-2766.

[39] [39] BOONPHENG B, THONGPRAYOON C, WIJARNPREECHA K, et al. Outcomes of patients with autosomal dominant polysytic kidney disease on peritoneal dialysis: a meta-analysis［J］. American Journal of Kidney Diseases the Official Journal of the National Kidney Foundation, 2018, 24(6): 638-646.

[40] [40] SCHREIBER R, BUCHHOLZ B, KRAUS A, et al. Lipid peroxidation drives renal cyst growth in vitro through activation of TMEM16A［J］. Journal of the American Society of Nephrology Jasn, 2019, 30(2): 228-242.?

[41] [41] ZUK A, BONVENTRE J V. Recent advances in acute kidney injury and its consequences and impact on chronic kidney disease［J］. Current Opinion in Nephrology and Hypertension, 2019, 28(4): 397-405.

[42] [42] FRIEDMANN ANGELI J P, SCHNEIDER M, PRONETH B, et al. Inactivation of the ferroptosis regulator Gpx4 triggers acute renal failure in mice［J］. Free Radical Biology & Medicine, 2014, 76(12): 1180-1191.

[43] [43] WENZEL S E, TYURINA Y Y, ZHAO J, et al. PEBP1 wardens ferroptosis by enabling lipoxygenase generation of lipid death signals［J］. Cell, 2017, 171(3): 628-641.

[44] [44] MARTIN-SANCHEZ D, RUIZ-ANDRES O, POVEDA J, et al. Ferroptosis, but not necroptosis, is important in nephrotoxic folic acid-induced aki［J］. Journal of the American Society of Nephrology Jasn, 2016, 28(1): 218-229.

[45] [45] ZHANG J, BI J, REN Y, et al. Involvement of GPX4 in irisin’s protection against isch emia reperfusion-induced acute kidney injury［J］. Journal of Cellular Physiology, 2021, 236(2): 931-945.?

[46] [46] HU Z, ZHANG H, YI B, et al. VDR activation attenuate cisplatin induced AKI by inhibiting ferroptosis［J］. Cell Death & Disease, 2020, 11(1): 73.

[48] [48] GUPTA P, VENUGOPAL S K. Augmenter of liver regeneration: a key protein in liver regeneration and pathophysiology［J］. Hepatology Research, 2018, 48(8): 587-596.

[49] [49] HUANG L L, LIAO X H, SUN H, et al. Augmenter of liver regeneration protects the kidney from ischaemia-reperfusion injury in ferroptosis［J］. Journal of Cellular and Molecular Medicine, 2019, 23(6): 4153-4164.

[50] [50] DING C, DING X, ZHENG J, et al. MiR-182-5p and miR-378a-3p regulate ferroptosis in I/R-induced renal injury［J］. Cell Death & Disease, 2020, 11(10): 929.

[51] [51] ZHAO Z, WU J, XU H, et al. XJB-5-131 inhibited ferroptosis in tubular epithelial cells after ischemiareperfusion injury［J］. Cell Death & Disease, 2020, 11(8): 629.

[52] [52] LUO M, WU L, ZHANG K, et al. MiR-137 regulates ferroptosis by targeting glutamine transporter SLC1A5 in melanoma［J］. Cell Death & Differentiation, 2018, 25(8): 1457-1472.